CTLA4 and melanoma: Meanwhile, the Kaplan-Meier Plotter database showed that WFDC13, highly expressed in melanoma and BLCA patients, indeed had a poor prognosis when they received anti-PD1, anti-PDL1, or anti-CTLA4 antibodies (Fig. A4A).